Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

New centre aims to Catapult UK into cell and gene therapy lead

New centre aims to Catapult UK into cell and gene therapy lead

and Gilead/Kite’s Yescarta, plus Spark Therapeutic’s AAV-based gene therapy. ... This makes it a unique resource and helps smaller companies scale up without having the resources of the big players such as Novartis and Gilead/Kite.

Latest news

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Last year, the first two CAR-T products - from Novartis and Gilead Sciences/Kite - were approved by the FDA.

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    fierce rivalry with Gilead Sciences. ... Its main rival is expected to be Gilead’s new fixed-dose regimen Biktarvy, which combines integrase inhibitor bictegravir with the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide)

  • Long-serving R&D head Bischofberger to leave Gilead Long-serving R&D head Bischofberger to leave Gilead

    Long-serving R&D head Bischofberger to leave Gilead. John McHutchison, currently executive VP of clinical research, will step into the role. ... at Gilead, with the last 11 years spent as chief scientific officer (CSO).

  • Gilead says switching studies back new HIV therapy Biktarvy Gilead says switching studies back new HIV therapy Biktarvy

    Gilead says switching studies back new HIV therapy Biktarvy. Patients who switched from rival Triumeq could maintain viral suppression over the trial period. ... share for ViiV, so Gilead will have to pull out all the stops to build momentum behind its

  • Gilead study resurrects HIV eradication hope Gilead study resurrects HIV eradication hope

    Gilead study resurrects HIV eradication hope. Intends to start human trials of its improved bNAb candidate. ... GS-9620 is already in early-stage clinical testing, and Gilead says that it now intends to start human trials of an improved bNAb candidate -

More from news
Approximately 126 fully matching, plus 295 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Gilead’s success with its curative Hep C portfolio had ultimately led to a diminishing population of target patients and played havoc with its revenues. ... Sanofi’s Lantus (-18.8%), Amgen’s Enbrel (-10.8%) and Gilead’s Harvoni (-48.5%) are among

  • Academic-industry collaboration in the era of big data Academic-industry collaboration in the era of big data

    Noteworthy international examples to this direction include Pfizer’s collaboration with seven New York medical institutes and eight Boston research institutions, Gilead’s with Yale University, AstraZeneca’s with the National

  • Pharma deals continue to slide Pharma deals continue to slide

    Given big pharma’s reluctance to spend on M&A it is perhaps surprising that this month Gilead has announced the $11.9bn acquisition of Kite Pharma. ... In this case Gilead’s cash mountain and the pressing need for a deal outweighed the uncertainty

  • Deal Watch - May 2017 Deal Watch - May 2017

    More recent data reported in FiercePharma (1. st. May) shows Amgen has cash overseas of $34bn, Gilead $27bn and Merck &Co $22bn.

  • When science is not enough When science is not enough

    Witness Gilead’s hepatitis C drug sovaldi (sofosbuvir) which has glowing efficacy results yet is having a troubled transition into the market place.

More from intelligence
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 15 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics